NKGN — Nkgen Biotech Share Price
0.000.00%
Last trade - 00:00- $5.71m
- $36.01m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 0.43 | 0.08 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
NKGen Biotech, Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapeutics. Its product candidates are based on a manufacturing and cryopreservation process, which produces SuperNK (SNK) cells. SNK cells can be produced in large quantities and cryopreserved, while maintaining high levels of cytotoxicity and activating receptor expression after thawing and reconstitution. It is developing SNK01, an autologous natural killer (NK) cell therapy, for the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). Its autologous NK cell therapy candidate has clinical trials in several therapeutic areas, including oncology and neurodegeneration. SNK02 is its allogeneic NK cell product candidate. It is conducting clinical trials with its SNK cell therapy in patients with neurodegenerative disease (SNK01) and cancer (SNK02).
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- January 28th, 2021
- Public Since
- May 21st, 2021
- No. of Employees
- 63
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 44,947,588
- Address
- 3001 Daimler St,, SANTA ANA, 92705
- Web
- https://nkgenbiotech.com/
- Phone
- +1 9493966830
- Auditors
- Ernst & Young LLP
Upcoming Events for NKGN
NKGen Biotech Inc Annual Shareholders Meeting
Q2 2025 NKGen Biotech Inc Earnings Release
Similar to NKGN
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Nkgen Biotech share price?
As of Today at 22:20 UTC, shares in Nkgen Biotech are trading at $0.13. This share price information is delayed by 15 minutes.
How has the Nkgen Biotech share price performed this year?
Shares in Nkgen Biotech last closed at $0.13 and the price had moved by -90.37% over the past 365 days. In terms of relative price strength the Nkgen Biotech share price has underperformed the S&P500 Index by -91.07% over the past year.
What are the analyst and broker recommendations for Nkgen Biotech?
There is no consensus recommendation for this security.
Find out moreWhat is the Nkgen Biotech dividend yield?
Nkgen Biotech does not currently pay a dividend.
Does Nkgen Biotech pay a dividend?
Nkgen Biotech does not currently pay a dividend.
When does Nkgen Biotech next pay dividends?
Nkgen Biotech does not currently pay a dividend.
How do I buy Nkgen Biotech shares?
To buy shares in Nkgen Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Nkgen Biotech?
As of the previous close price of $0.13, shares in Nkgen Biotech had a market capitalisation of $5.71m.
Where are Nkgen Biotech shares listed?
Here are the trading details for Nkgen Biotech:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: NKGN
What kind of share is Nkgen Biotech?
Based on an overall assessment of its quality, value and momentum Nkgen Biotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Nkgen Biotech share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Nkgen Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Nkgen Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -52.31%.
As of the last closing price of $0.13, shares in Nkgen Biotech were trading -74.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Nkgen Biotech PE Ratio?
The Nkgen Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.13.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Nkgen Biotech?
We do not have data on Nkgen Biotech's directors